Loss of Dab2 expression in breast cancer cells impairs their ability to deplete TGF-β and induce Tregs development via TGF-β.
about
Switching Roles of TGF-β in Cancer Development: Implications for Therapeutic Target and Biomarker StudiesDab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy.Integrin traffic - the update.miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
P2860
Loss of Dab2 expression in breast cancer cells impairs their ability to deplete TGF-β and induce Tregs development via TGF-β.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Loss of Dab2 expression in bre ...... e Tregs development via TGF-β.
@ast
Loss of Dab2 expression in bre ...... e Tregs development via TGF-β.
@en
type
label
Loss of Dab2 expression in bre ...... e Tregs development via TGF-β.
@ast
Loss of Dab2 expression in bre ...... e Tregs development via TGF-β.
@en
prefLabel
Loss of Dab2 expression in bre ...... e Tregs development via TGF-β.
@ast
Loss of Dab2 expression in bre ...... e Tregs development via TGF-β.
@en
P2093
P2860
P1433
P1476
Loss of Dab2 expression in bre ...... e Tregs development via TGF-β.
@en
P2093
Jingzhi Zhu
Shuguang Xu
Zhiyong Wu
P2860
P304
P356
10.1371/JOURNAL.PONE.0091709
P407
P577
2014-03-17T00:00:00Z